This company is no longer active
WntResearch (WNT) Stock Overview
A biotech company, develops therapies to prevent the metastatic process. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
WNT Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
WntResearch AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.49 |
| 52 Week High | SEK 17.20 |
| 52 Week Low | SEK 0.40 |
| Beta | -0.21 |
| 1 Month Change | -41.59% |
| 3 Month Change | -32.47% |
| 1 Year Change | n/a |
| 3 Year Change | -98.93% |
| 5 Year Change | -99.73% |
| Change since IPO | -99.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| WNT | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -13.2% | -0.9% | 0.4% |
| 1Y | n/a | 28.5% | 15.1% |
Return vs Industry: Insufficient data to determine how WNT performed against the Swedish Biotechs industry.
Return vs Market: Insufficient data to determine how WNT performed against the Swedish Market.
Price Volatility
| WNT volatility | |
|---|---|
| WNT Average Weekly Movement | 21.8% |
| Biotechs Industry Average Movement | 10.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in SE Market | 13.9% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: WNT's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: WNT's weekly volatility (22%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 2 | Per Goran Norlen | www.wntresearch.com |
WntResearch AB, a biotech company, develops therapies to prevent the metastatic process. The company develops Foxy-5, a peptide, which is in Phase II clinical trials that reduced the risk of metastasis in patients with colon cancer. It is also developing Box-5, a WNT5A antagonist for the treatment of malignant melanoma, and pancreatic and gastric cancer.
WntResearch AB Fundamentals Summary
| WNT fundamental statistics | |
|---|---|
| Market cap | SEK 4.27m |
| Earnings (TTM) | -SEK 46.50m |
| Revenue (TTM) | n/a |
Is WNT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| WNT income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 0 |
| Other Expenses | SEK 46.50m |
| Earnings | -SEK 46.50m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.37 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did WNT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/07 14:34 |
| End of Day Share Price | 2025/04/04 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
WntResearch AB is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gustaf Meyer | Redeye |